Mylan N.V. (MYL) EPS Estimated At $1.00

April 22, 2018 - By Richard Conner

Mylan N.V. (NASDAQ:MYL) LogoInvestors sentiment increased to 3 in 2017 Q4. Its up 2.67, from 0.33 in 2017Q3. It is positive, as 0 investors sold Mylan N.V. shares while 1 reduced holdings. 3 funds opened positions while 0 raised stakes. 292,846 shares or 88.91% more from 155,019 shares in 2017Q3 were reported.
Mirae Asset Global holds 0.01% of its portfolio in Mylan N.V. (NASDAQ:MYL) for 17,231 shares. Gulf State Bank (Uk) Ltd accumulated 139,930 shares or 0.08% of the stock. Van Hulzen Asset Mgmt Limited Co holds 120,545 shares. Vantage Investment Advsr Ltd Liability Company holds 337 shares.

Analysts expect Mylan N.V. (NASDAQ:MYL) to report $1.00 EPS on May, 9.They anticipate $0.07 EPS change or 7.53 % from last quarter’s $0.93 EPS. MYL’s profit would be $514.78 million giving it 10.18 P/E if the $1.00 EPS is correct. After having $1.43 EPS previously, Mylan N.V.’s analysts see -30.07 % EPS growth. The stock decreased 0.22% or $0.09 during the last trading session, reaching $40.72. About 3.09 million shares traded. Mylan N.V. (NASDAQ:MYL) has declined 5.23% since April 22, 2017 and is downtrending. It has underperformed by 16.78% the S&P500.

Mylan N.V. (NASDAQ:MYL) Ratings Coverage

Among 14 analysts covering Mylan Inc (NASDAQ:MYL), 11 have Buy rating, 0 Sell and 3 Hold. Therefore 79% are positive. Mylan Inc had 23 analyst reports since October 23, 2017 according to SRatingsIntel. Morgan Stanley maintained the shares of MYL in report on Monday, April 9 with “Buy” rating. The firm has “Buy” rating given on Thursday, January 25 by Susquehanna. The firm earned “Buy” rating on Tuesday, December 12 by Guggenheim. The stock of Mylan N.V. (NASDAQ:MYL) has “Buy” rating given on Tuesday, November 7 by Susquehanna. BMO Capital Markets maintained Mylan N.V. (NASDAQ:MYL) on Tuesday, February 6 with “Buy” rating. The firm has “Hold” rating by Cantor Fitzgerald given on Thursday, December 21. The stock of Mylan N.V. (NASDAQ:MYL) has “Hold” rating given on Thursday, March 1 by Cantor Fitzgerald. The company was maintained on Thursday, January 18 by Mizuho. The rating was maintained by UBS with “Buy” on Monday, December 4. As per Tuesday, April 3, the company rating was maintained by RBC Capital Markets.

Mylan N.V., together with its subsidiaries, develops, licenses, makes, markets, and distributes generic, brand name, and over-the-counter products worldwide. The company has market cap of $20.96 billion. The firm operates through three divisions: North America, Europe, and Rest of World. It has a 31.32 P/E ratio. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.

Mylan N.V. (NASDAQ:MYL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: